Prostate Cancer - Results from #21780

Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy - Abstract November 19, 2013

Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: Correlation with Gleason score of prostate cancer - Abstract November 19, 2013

Fully automated prostate segmentation on MRI: Comparison with manual segmentation methods and specimen volumes - Abstract November 19, 2013

Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: Results from a prospectively screened population cohort - Abstract November 19, 2013

Systematic review: Anal and rectal changes after radiotherapy for prostate cancer - Abstract November 19, 2013

PSA screening in New Zealand: Total population results and general practitioners' current attitudes and practices - Abstract November 19, 2013

Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer - Abstract November 19, 2013

A urologic oncology roundtable discussion: Issues to consider in choosing treatment for metastatic castration-resistant prostate cancer - Abstract November 19, 2013

Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration Drug Approval Summary - Abstract November 19, 2013

Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy - Abstract November 18, 2013

Permanent prostate brachytherapy extracapsular radiation dose distributions: Analysis of a multi-institutional database - Abstract November 18, 2013

A urologic oncology roundtable discussion: The role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer - Abstract November 18, 2013

A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy - Abstract November 18, 2013

Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: A competing risk regression analysis - Abstract November 18, 2013

External validation of preoperative nomograms predicting biochemical recurrence after radical prostatectomy - Abstract November 18, 2013

Regional variation in quality of prostate cancer care - Abstract November 18, 2013

Psychological impact of prostate biopsy: Physical symptoms, anxiety, and depression - Abstract November 18, 2013

Robust plan optimization for electromagnetic transponder guided hypo-fractionated prostate treatment using volumetric modulated arc therapy - Abstract November 18, 2013

Cancer-associated bone disease - Abstract November 18, 2013

Algeta ASA: Xofigo® (radium Ra 223 dichloride) granted marketing authorization in the European Union November 15, 2013

Page 1090 of 1435